An official website of the United States government
CAR-T Long Term Follow Up (LTFU) Study
Trial Status: active
Per Health Authorities guidelines for gene therapy medicinal products that utilize
integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of
treated patients is required. The purpose of this study is to monitor all patients
exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion
to assess the risk of delayed adverse events (AEs), monitor for replication competent
lentivirus (RCL) and assess long-term efficacy, including vector persistence.
Inclusion Criteria
All patients who have received a CAR-T therapy and completed or discontinued early from a Novartis sponsored treatment protocol that utilized CAR-T cells or from any CAR-T trial sponsored by the University of Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR technology.
Patients who have provided informed consent for the long term follow up study prior to their study participation .
Exclusion Criteria
There are no specific exclusion criteria for this study.
Additional locations may be listed on ClinicalTrials.gov for NCT02445222.
